Title
The role of Tumour Necrosis Factor in neuroinflammation associated with Parkinson's disease and targeted therapies
Date Issued
01 September 2022
Access level
metadata only access
Resource Type
review
Author(s)
Amin R.
Docea A.O.
Ydyrys A.
Kulbayeva M.
Durna Daştan S.
Calina D.
Sharifi-Rad J.
Universidad Arturo Prat
Publisher(s)
Elsevier Ltd
Abstract
Neurodegenerative disorders Parkinson's disease is a progressive neurodegenerative disorder associated with neuroinflammatory responses that lead to the neurodegeneration of the dopaminergic neurons. These neuroinflammatory mechanisms involve various cytokines produced by the activated glial cells. Tumour Necrosis factor α (TNF α) is one of the major mediators of the neuroinflammation associated with neurodegeneration. TNF α has a dual role of neuroprotection and neurotoxicity in the brain. The effective pathways of TNF involve various signalling pathways transduced by the receptors TNFR1 and TNFR2. Effective therapeutic strategies have been produced targeting the neurotoxic behaviour of the Tumour Necrosis Factor and the associated neurodegeneration which includes the use of Dominant Negative Tumour Necrosis Factor (DN-TNF) inhibitors like XENP 345 and XPro®1595 and peroxisome proliferator receptor gamma (PPAR-γ) agonists.
Volume
158
Language
English
OCDE Knowledge area
Neurociencias
Scopus EID
2-s2.0-85131409426
PubMed ID
Source
Neurochemistry International
ISSN of the container
01970186
Sources of information: Directorio de Producción Científica Scopus